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Abstract
Diabetes mellitus is a group of diseases defined by persistent hyperglycaemia. Type 2 diabetes, the 
most prevalent form, is characterised initially by impaired insulin sensitivity and subsequently by 
an inadequate compensatory insulin response. Diabetes can also develop as a direct consequence 
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of other diseases, including diseases of the exocrine pancreas. Historically, diabetes due to 
diseases of the exocrine pancreas was described as pancreatogenic or pancreatogenous diabetes 
mellitus, but recent literature refers to it as type 3c diabetes. It is important to note that type 3c 
diabetes is not a single entity; it occurs because of a variety of exocrine pancreatic diseases with 
varying mechanisms of hyperglycaemia. The most commonly identified causes of type 3c diabetes 
are chronic pancreatitis, pancreatic ductal adenocarcinoma, haemochromatosis, cystic fibrosis, and 
previous pancreatic surgery. In this Review, we discuss the epidemiology, pathogenesis, and 
clinical relevance of type 3c diabetes secondary to chronic pancreatitis and pancreatic ductal 
adenocarcinoma, and highlight several important knowledge gaps.
Introduction
Diabetes mellitus is a group of diseases defined by persistent hyperglycaemia.1 The most 
prevalent form is type 2 diabetes, which is characterised initially by impaired insulin 
sensitivity and subsequently by an inadequate compensatory insulin response. However, 
diabetes can also develop as a direct consequence of other diseases, including diseases of the 
exocrine pancreas.
Historically, diabetes due to diseases of the exocrine pancreas was described as 
pancreatogenic or pancreatogenous diabetes mellitus, but recent literature refers to it as type 
3c diabetes. The origin of this term is attributed to a table published annually by the 
American Diabetes Association until 2014,2 which listed four broad types of diabetes in an 
outline format with III.C indicating diabetes secondary to diseases of the exocrine pancreas, 
which authors have variably referenced as type IIIC diabetes mellitus and type 3c diabetes 
mellitus. We favour the term type 3c diabetes mellitus because the use of an Arabic numeral 
avoids confusion between the Roman numerals for two and three, and is consistent with 
nomenclature used for type 1 and type 2 diabetes. The lower case “c” is most commonly 
used in existing literature, so we have also adopted this. However, in contrast to type 1 and 
type 2 diabetes, it is important to recognise that the term type 3c diabetes incorporates 
causes of diabetes with different pathophysiologies, which are combined solely for the 
purposes of classification (panel).
Additional understanding of the different causes of type 3c diabetes is needed to allow us to 
more precisely define (and name) the different subtypes. We anticipate this nomenclature 
will undergo future refinement. The two major causative factors in the pathogenesis of 
diabetes are inadequate pancreatic β-cell function and insulin resistance. These two factors 
appear to contribute differentially to the hyperglycaemia observed in patients with type 3c 
diabetes. A comprehensive explanation of the physiology and methods of analysing insulin 
action and secretion is beyond the scope of this Review, but a synopsis is provided for 
context in the appendix.
The most commonly identified cause of type 3c diabetes is chronic pancreatitis. For 
example, in a large single-centre review, the distribution of causes for type 3c diabetes 
consisted of chronic pancreatitis (79%), pancreatic ductal adenocarcinoma (8%), 
haemochromatosis (7%), cystic fibrosis (4%), and previous pancreatic surgery (2%; figure).3 
The following discussion will focus on type 3c diabetes secondary to chronic pancreatitis 
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and pancreatic ductal adenocarcinoma on the basis of their disease prevalence and clinical 
significance.
Estimated prevalence
The true worldwide prevalence of type 3c diabetes is unknown, but there are two possible 
approaches to generate an estimate. The first approach applies the reported prevalence of 
diabetes in pancreatic diseases from cohort studies to a broader population. Globally, the 
incidence of chronic pancreatitis is estimated at 33.7 cases per 100000 person-years and 
pancreatic ductal adenocarcinoma 8.1 cases per 100000 person-years.4 In the USA, the 
estimated number of prevalent cases of chronic pancreatitis is 150 000–175 000 and of 
pancreatic ductal adenocarcinoma is 50 000.5,6 Application of the prevalence of diabetes in 
chronic pancreatitis (up to about 80%) and pancreatic ductal adenocarcinoma (about 50%) to 
these estimates would yield at least 150000 cases of type 3c diabetes, or approximately 0.5–
1% of all patients with diabetes (based on a US prevalence of 22 million in 2014). The 
second approach is to determine the prevalence of pancreatic diseases in a cohort of patients 
with diabetes, then apply this estimate to everyone in the population with diabetes. The 
largest study to assess prevalence among a cohort with diabetes classified 172 (9.2%) of 
1868 as having type 3c diabetes.3 However, several factors are likely to have inflated this 
prevalence, including unresolved questions regarding whether or not the test abnormalities 
observed (eg, decreased faecal elastase-1 value) are a consequence of a disease of the 
exocrine pancreas or a secondary effect of diabetes (recently termed diabetic exocrine 
pancreatopathy7). A smaller study in 150 participants with diabetes reported a 5.4% 
prevalence of type 3c diabetes.8 Until additional studies are completed, it is reasonable to 
assume that the true prevalence of type 3c diabetes probably ranges from 1% to 9% of 
patients with diabetes, and 4–5% might be a reasonable working estimate.
Diagnostic criteria for type 3c diabetes
There are no universally accepted diagnostic criteria for type 3c diabetes. Conceptually, the 
diagnosis can be made in patients who meet the three following criteria: those who fulfil the 
diagnostic criteria for diabetes, those who have a disease of the exocrine pancreas, and those 
whose diabetes is reasonably certain to be secondary to their exocrine pancreatic disease.
In the only published criteria for type 3c diabetes, Ewald and Bretzel9 proposed the 
following major criteria (all must be present): exocrine pancreatic insufficiency (by 
monoclonal faecal elastase-1 testing or direct function tests), consistent pancreatic 
abnormalities on imaging (endoscopic ultrasound, MRI, or CT scan), and absence of related 
autoimmune markers of type 1 diabetes.9 Minor criteria included impaired β-cell function 
(as measured by homoeostatic model assessment for β-cell function, or C-peptide or glucose 
concentrations), absence of insulin resistance (as defined by homoeostatic model assessment 
for insulin resistance), impaired incretin secretion (glucagon-like peptide-1 [GLP-1] or 
pancreatic polypeptide, or both), and low serum concentrations of lipid soluble vitamins (A, 
D, E, and K). However, these criteria are limited by several important factors, including 
overlap of features with long-standing type 1 and 2 diabetes (appendix), little standardisation 
in methods used to determine inadequate β-cell function and insulin resistance, absence of 
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high-quality published data for glucose homoeostasis in type 3c diabetes, the presence of 
coexistent insulin resistance in many patients, and the availability of adequate radiological 
and laboratory resources. Clinical characteristics of patients could help to further refine 
diagnostic criteria (appendix). In the absence of a definitive marker, the causality of diabetes 
due to exocrine disease is made either by the presence of advanced destruction or surgical 
removal of the pancreas, or recent onset of diabetes in the setting of pancreatic ductal 
adenocarcinoma.
Diabetes secondary to chronic pancreatitis
Type 3c diabetes is a frequent comorbidity of chronic pancreatitis, with prevalence estimates 
ranging from 25% to 80%.10–14 Increased disease duration is an important risk factor for 
diabetes secondary to chronic pancreatitis. In hereditary pancreatitis, the median age of 
onset of diabetes is between 38 and 53 years, but the age of onset of diabetes is less well 
characterised in the acquired forms of chronic pancreatitis.11,12
During the past two decades, there have been tremendous advancements in understanding of 
the genetic determinants of chronic pancreatitis, which predominantly modify the risk for 
development and progression of disease.15 However, no systematic studies to date have 
examined the potential genetic differences between type 3c diabetes secondary to chronic 
pancreatitis (or pancreatic cancer) and type 2 diabetes (or other subtypes of diabetes).
Complications
Data for acute metabolic complications, such as hypoglycaemia and diabetic ketoacidosis, in 
pancreatic disorders are scarce. In one series of 36 patients with diabetes associated with 
chronic pancreatitis, 78% of those treated with insulin reported hypoglycaemia and 17% had 
severe hypoglycaemia.16 Data for traditional target organ complications from type 3c 
diabetes are similarly scarce. In the only prospective study to date, 54 patients with type 3c 
diabetes due to chronic pancreatitis or total pancreatectomy were studied.17 The risk of 
diabetic retinopathy was 31% and correlated with the duration of diabetes. In separate 
studies, diabetic retinopathy (37%), diabetic nephropathy (29%), and peripheral arterial 
disease (26%) developed in patients from the respective cohorts.18,19 However, many of 
these studies were published decades ago with variable study designs, so extrapolations of 
available data are not reliable. Prospectively, smoking, hypertension, hyperlipidaemia, and 
obesity are expected to influence target organ complications and should be studied 
concurrently with type 3c diabetes.
Increased risk of pancreatic cancer
Because both diabetes mellitus and chronic pancreatitis are risk factors for pancreatic ductal 
adenocarcinoma, the combination might particularly increase concern for progression to 
pancreatic ductal adenocarcinoma.20 In a population-based cohort study in Taiwan, the risk 
of pancreatic ductal adenocarcinoma was substantially elevated in participants with 
concurrent diabetes and chronic pancreatitis (hazard ratio 33.5).21 Separate database studies 
also showed an increased, but more modest, risk ratio (4.7–12.1) of pancreatic ductal 
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adenocarcinoma in those with otherwise unclassified diabetes and a history of chronic 
pancreatitis.22,23 Additional validation in other cohorts is needed.
Mechanisms of hyperglycaemia
Insulin deficiency—A key mechanism underlying the high risk of diabetes in chronic 
pancreatitis is deficient insulin production. Cross-sectional studies of patients with chronic 
pancreatitis suggest progressive insulin deficiency, with mild insulin deficiency present even 
before the development of diabetes, but more severe deficiency in chronic pancreatitis with 
type 3c diabetes.24,25 In another cross-sectional study of patients without diabetes but with 
chronic pancreatitis, some of whom had impaired fasting glucose, the disposition index (a 
measure of insulin secretion adjusted for insulin sensitivity from the frequently sampled 
intravenous glucose tolerance test) was lower in the chronic pancreatitis group than in 
healthy controls matched for age, sex, and body-mass index, with the most pronounced 
deficits in those with chronic calcific pancreatitis.26 Endocrine function tends to decline in 
parallel with exocrine function, although frank diabetes is likely to occur later in the course 
of the disease.27
Two potential mechanisms might underlie this clinical observation of relative insulin 
deficiency. First, even early in the course of chronic pancreatitis, the inflammatory 
environment and increased concentration of cytokines within the pancreatic parenchyma 
have been postulated to mediate β-cell dysfunction before frank β-cell loss.28 Second, as 
chronic pancreatitis progresses, the extensive fibrosis of the exocrine pancreas slowly 
destroys the pancreatic islet tissue. Decreased insulin secretion in diabetes secondary to 
chronic pancreatitis has been shown to correlate with decreased pancreatic and β-cell mass, 
which is the mechanism of type 3c diabetes after partial or total pancreatectomy.29
Potential immunopathogenesis—Inhibition of glucose-stimulated insulin release by 
proinflammatory cytokines, including interleukin 1β, tumour necrosis factor (TNF) α, and 
interferon γ, has been demonstrated.30 Islets expressing high concentrations of interleukin 
1R and interleukin 1β induce β-cell apoptosis.31 Clinical studies of antagonists to 
interleukin 1R, interleukin 1β, and TNFα have shown some efficacy in type 2 diabetes.32 
Increased expression of interferon γ results in impaired translocation of the islet cell 
transcription factor PDX-1 in patients with chronic pancreatitis.33 This loss of PDX-1 
localisation to the nucleus can be reversed by specific inhibition of interferon γ. 
Additionally, adrenomedullin and vanin-1, which are also expressed in response to 
inflammation, probably play an important part in altered islet cell function in type 3c 
diabetes caused by both chronic pancreatitis and pancreatic ductal adenocarcinoma.34 
Studies are needed to further examine these inflammatory mediators, as well as the role of 
interleukin 10, interleukin 12, and other cytokines in diabetes secondary to chronic 
pancreatitis (appendix), to better contrast the different immunopathogenesis compared with 
type 2 diabetes.
Hepatic insulin resistance—Hepatic insulin resistance has been demonstrated in 
patients with type 3c diabetes secondary to pancreatic resection, chronic pancreatitis, 
pancreatic ductal adenocarcinoma, and cystic fibrosis.35–38 The cause of persistent hepatic 
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glucose production and isolated hepatic insulin resistance in type 3c diabetes appears to be 
multifactorial, with a deficient pancreatic polypeptide response playing a key part 
(appendix). Pancreatic polypeptide regulates the expression and availability of hepatic 
insulin receptors, and the diminished insulin receptor availability in chronic pancreatitis can 
be reversed by pancreatic polypeptide administration.39–41 Data from clamp studies in 
patients with pancreatic polypeptide deficiency and chronic pancreatitis showed that 
pancreatic polypeptide administration reversed the hepatic insulin resistance.36 In a 
subsequent randomised, blinded, placebo-controlled study, a 72 h subcutaneous infusion of 
pancreatic polypeptide improved overall insulin sensitivity in pancreatic polypeptide-
deficient patients with type 1 and type 3c diabetes.42 Pancreatic polypeptide deficiency is a 
common finding in all forms of type 3c diabetes studied thus far, and these studies show that 
pancreatic polypeptide is a glucoregulatory hormone that regulates hepatic insulin 
sensitivity.
In addition to altered insulin receptor availability, altered hepatic insulin function in chronic 
pancreatitis has also been linked to the inflammation-based activation of hepatocyte I-κB 
kinase-β and NF-κB.43 Blockade of NF-κB activation results in improved hepatic insulin 
sensitivity.44 This effect can be achieved by activation of peroxisome proliferator-activated 
receptor-γ, which is the mechanism of action of the thiazolidinedione class of antidiabetic 
drugs. Rosiglitazone has been shown to reverse hepatic insulin resistance in rats with 
chronic pancreatitis, but has not been rigorously studied in human beings.45
Peripheral insulin resistance—Accurate methods for measurement of insulin 
sensitivity and insulin secretion (including the euglycaemic– hyperinsulinaemic clamp and 
frequently sampled intravenous glucose tolerance test) have demonstrated the presence of 
insulin resistance in chronic pancreatitis. Insulin resistance is commonly observed and 
appears to be independent of other components of the metabolic syndrome.46 In clamp 
studies of patients with both chronic pancreatitis and diabetes, the degree of total-body 
insulin sensitivity (which primarily reflects peripheral insulin-mediated glucose uptake) was 
less than that observed in healthy controls or in patients with type 1 diabetes.47,48 Another 
clamp study using tracers (which can assess endogenous [hepatic] glucose production, and 
are normally suppressed by insulin) found elevated basal endogenous glucose production 
that was suppressible during hyperinsulinaemic infusion in patients with type 3c diabetes 
compared with controls.48 By contrast, one group’s clamp studies showed increased insulin 
sensitivity in patients with type 3c diabetes compared with type 1 diabetes.49,50 These 
studies suggest that insulin resistance is probably a contributing factor to diabetes secondary 
to chronic pancreatitis; however, further studies are needed to confirm this notion, and 
establish whether the observed insulin resistance is a cause or consequence of 
hyperglycaemia.
Reduced incretin effect—The incretin effect refers to the greater insulin response 
observed with oral glucose loading compared with an equivalent intravenous glucose load. 
This effect is mainly mediated by rapid meal-induced secretion of hormone signals from the 
gastrointestinal tract that promote insulin secretion (enteroinsular axis). The primary incretin 
hormones are glucose-dependent insulinotropic polypeptide (GIP), which is secreted by K 
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cells in the small intestine, and GLP-1, which is mainly secreted by L cells in the ileum and 
large intestine. Both of these hormones are rapidly inactivated by dipeptidyl peptidase 4 
(DPP-4), and augment insulin secretion in a glucose-dependent manner. In type 2 diabetes, 
deficient secretion of GLP-1 and resistance to GIP has been suggested.51 In type 3c diabetes, 
the sensitivity to GLP-1 seems to be intact, while the late-phase insulin secretion response to 
GIP is reduced similarly to that in type 2 diabetes.52–54
Because many patients with chronic pancreatitis often develop exocrine pancreatic 
insufficiency, a leading hypothesis is that impaired nutrient absorption might result in a 
reduced incretin response to meals, with consequently reduced postprandial insulin 
secretion. However, results of studies have been mixed in this regard and some investigators 
have concluded that the reduced incretin effect is a consequence, not a cause, of the diabetic 
state.55–57 Additional studies have had discrepant results, which might be a consequence of 
small sample size (<ten participants in each group) and inaccurate incretin assays. These 
conflicting reports suggest the need for a comprehensive examination of basal and 
stimulated incretin responses.
Interactions between exocrine pancreatic insufficiency and glucose homoeostasis
Given that nutrient ingestion stimulates incretin secretion, investigators have sought to 
establish whether pancreatic enzyme replacement therapy (PERT) for patients with exocrine 
pancreatic insufficiency would stimulate incretin secretion, thereby improving glycaemic 
control. The premise is that digestion and absorption of nutrients, not simply their luminal 
presence, might be important for incretin production. The table shows the available data 
characterising incretin, glycaemic, and pancreatic islet hormonal responses to PERT in 
patients with chronic pancreatitis and cystic fibrosis.55,57–59 These small, but well done, 
studies assessed hormonal responses with and without PERT with a meal challenge. Despite 
the heterogeneity of these studies, they uniformly showed that PERT resulted in increased 
postprandial responses in GIP and GLP-1; however, the predicted concomitant increase in 
insulin response was observed only in chronic pancreatitis. It has also been suggested that 
improved glycaemic control in type 2 diabetes can improve the incretin response, so 
additional efforts are needed to understand these complex relationships. The available data 
are compelling, but further studies are needed to investigate the use of PERT in patients with 
chronic pancreatitis to assess the potential to improve glycaemic control.
Management of hyperglycaemia
There are no head-to-head comparison studies to determine the relative safety and efficacy 
of available antidiabetic therapies in chronic pancreatitis. Thus, treatment is extrapolated 
from the pathophysiology of diabetes secondary to chronic pancreatitis and the known risk 
of pancreatic ductal adenocarcinoma in the setting of chronic pancreatitis and diabetes. 
Metformin or insulin is used as first-line therapy, and their use might be tailored to the 
specific presentation of the patient. Available data from cohort studies suggest that at least 
half of those with diabetes secondary to chronic pancreatitis are treated with insulin 
therapy.10,11 Insulin therapy addresses the insulin deficiency present in the disease, which is 
recommended by consensus guidelines in advanced diabetes secondary to chronic 
pancreatitis.60 However, there is a risk of hypoglycaemia with insulin therapy, particularly in 
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patients with chronic pancreatitis who might have enhanced peripheral insulin sensitivity.61 
By contrast, early in the course of diabetes secondary to chronic pancreatitis, particularly if 
hyperglycaemia is mild (HbA1c <8% or <64 mmol/mol), metformin alone might be 
considered as a first-line agent. Metformin has a theoretical advantage compared with 
insulin, in that it might be protective against pancreatic ductal adenocarcinoma; however, 
findings from previous studies might not be extrapolated to the setting of chronic 
pancreatitis, which has a different physiology to that of type 2 diabetes, particularly with 
regards to the presence of insulin deficiency in chronic pancreatitis compared with 
hyperinsulinism in type 2 diabetes.
The role of other antidiabetic agents is unclear. The incretin-based therapies—injectable 
GLP-1 analogues and oral DPP-4 inhibitors—are typically avoided in chronic pancreatitis 
because of their potential role in increasing risk for acute pancreatitis and pancreatic ductal 
adenocarcinoma.62 The thiazolidinediones increase both hepatic and peripheral insulin 
sensitivity but carry an increased risk of bone fracture, so their use might not be well suited 
for patients who are already at increased risk for this complication.
Diabetes secondary to pancreatic cancer
The association between pancreatic ductal adenocarcinoma and diabetes has been 
recognised for more than 150 years, and has been examined in more than 50 case-control 
and cohort studies. Meta-analyses of these studies have consistently shown a 1.5–2 times 
increased risk of pancreatic ductal adenocarcinoma in patients with long-standing (>5 years) 
diabetes, and a greater risk in individuals with diabetes duration of less than 5 years. Type 2 
diabetes is associated with insulin resistance, variable insulin concentrations, an inability of 
the liver to suppress inappropriate hepatic glucose release, and an inability of the β cells to 
overcome insulin resistance. In addition to β-cell dysfunction mediated by inflammation, β-
cell loss can occur as a consequence of oxidative stress and aberrant activation of the 
unfolded protein response pathway, which can induce both apoptosis and cell senescence 
leading to a decreased β-cell mass.63,64 Additionally, type 2 diabetes is often associated with 
obesity, which independently increases the risk for developing pancreatic ductal 
adenocarcinoma.65 Both conditions can lead to increased insulin in the pancreatic 
microenvironment, which promotes tumour development (appendix). Collectively, these 
changes are believed to partly explain the modest increased risk for pancreatic ductal 
adenocarcinoma in those with long-standing type 2 diabetes.
In a meta-analysis, Ben and colleagues66 reported a relative risk of 5.4 (95% CI 3.5–8.3) 
associated with diabetes of less than 1 year duration, with modest risk of about 1.5 times 
after 5 years of diabetes. Although the vast majority (>95%) of patients older than 50 years 
with new-onset diabetes have type 2 diabetes, a small proportion has a variety of other 
causes of diabetes (eg, late-onset type 1 diabetes, Cushing’s syndrome, or chronic 
pancreatitis). A population-based study from Rochester, MN, USA, found that 
approximately 1% of participants with new-onset diabetes at age 50 years or older have 
diabetes secondary to pancreatic cancer.67 In other studies, subsets of participants with 
recently diagnosed diabetes have been found to have an even higher prevalence of pancreatic 
ductal adenocarcinoma (5.2–13.6%).68–70 Thus, although long-standing diabetes modestly 
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increases the risk of pancreatic ductal adenocarcinoma, new-onset diabetes appears to be a 
marker of underlying pancreatic ductal adenocarcinoma in an important subset.
Hypotheses for increased prevalence of diabetes
Shared risk factors—Because canonical risk factors for type 2 diabetes—eg, old age, 
obesity, and family history of diabetes—are also risk factors for diabetes secondary to 
pancreatic cancer, there is a possibility that increased prevalence of diabetes in pancreatic 
ductal adenocarcinoma is an artifact of screening for diabetes in an elderly population.71 
However, a study comparing the prevalence of diabetes in common cancers (breast, lung, 
prostate, and colon) showed no increased prevalence of diabetes compared with age-matched 
controls, although the high prevalence of diabetes in pancreatic ductal adenocarcinoma, 
especially recent-onset diabetes, was confirmed.72
Glandular destruction—If the diabetes observed in pancreatic ductal adenocarcinoma 
were a consequence of glandular destruction, hypoinsulinaemia would be expected; 
however, diabetes secondary to pancreatic cancer is associated with hyperinsulinaemia 
secondary to insulin resistance. In fact, the median duration of diabetes in pancreatic ductal 
adenocarcinoma is about 13 months, at a time when imaging studies show no visible 
tumour.73,74 Moreover, 60% of small tumours (<20 mm in size) are associated with glucose 
intolerance, and more than half of patients with resectable tumours have diabetes.71,72,75 
Thus, there is insufficient evidence to support the hypothesis that diabetes secondary to 
pancreatic cancer is due to local effects of tumour infiltration, ductal obstruction, and 
consequently glandular destruction.76
Pancreatic ductal adenocarcinoma causes diabetes—The markedly increased risk 
of pancreatic ductal adenocarcinoma in new-onset diabetes appears to be due to reverse 
causality—ie, pancreatic ductal adenocarcinoma causes hyperglycaemia. This notion is 
supported by a large body of clinical, epidemiological, and experimental evidence. First, 
there is an exceedingly high prevalence of diabetes in the setting of pancreatic ductal 
adenocarcinoma, irrespective of the method of diagnosis. Approximately 80% of patients 
with pancreatic ductal adenocarcinoma have abnormal fasting glucose or glucose intolerance 
regardless of tumour size or stage.37,71,77 When formally tested with oral glucose tolerance 
tests, nearly two-thirds of patients with pancreatic ductal adenocarcinoma have 
diabetes.37,77,78 When screened for diabetes with fasting glucose, the prevalence is about 
45%.71 Second, the onset of diabetes is often temporally related to the diagnosis of 
pancreatic ductal adenocarcinoma.79 Most patients (75–88%) reported that diabetes was new 
onset—ie, diagnosed less than 24–36 months before diagnosis of pancreatic ductal 
adenocarcinoma.73,80,81 Third, effective treatment of pancreatic ductal adenocarcinoma 
often leads to improvement in hyperglycaemia for those with new-onset diabetes secondary 
to pancreatic cancer. Resection of the tumour improves or resolves diabetes in many patients 
with new-onset diabetes, although there is no improvement in those with long-standing 
diabetes.71 Similarly, the metabolic defects are improved in those who have a treatment 
response to chemotherapy.82 Lastly, pancreatic tumours might indirectly induce 
hyperglycaemia. Addition of conditioned media from pancreatic ductal adenocarcinoma cell 
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lines impairs glucose metabolism in vitro in peripheral tissues and inhibits insulin release 
from β-cell lines.83–86
Mechanisms of hyperglycaemia
Insulin resistance—Type 3c diabetes due to pancreatic ductal adenocarcinoma appears to 
differ fundamentally from other causes of type 3c diabetes in that it is not due to fibro-
inflammatory destruction or pancreatectomy. Rather, the previous line of reasoning indicates 
diabetes secondary to pancreatic cancer is probably a paraneoplastic effect due to mediators 
released by the cancer.76 However, the mechanisms of diabetes remain uncertain, with 
evidence suggesting that both insulin resistance and β-cell dysfunction improve with cancer 
resection in pancreatic ductal adenocarcinoma.
Whole body physiology studies have consistently shown that diabetes in pancreatic ductal 
adenocarcinoma is associated with substantial insulin resistance.78 In a series of studies, 
primarily performed by Permert and colleagues,77,78,87–89 there is decreased glucose 
metabolic capacity (ie, insulin resistance) in participants with pancreatic ductal 
adenocarcinoma, which is more pronounced in participants with diabetes, but also present in 
those with normoglycaemia and pancreatic ductal adenocarcinoma. Therefore, investigators 
have sought to identify putative mediators of insulin resistance in pancreatic ductal 
adenocarcinoma. In an early study, investigators showed that concentrations of plasma islet 
amyloid polypeptide were elevated in participants with pancreatic ductal adenocarcinoma 
who have diabetes, and they postulated that it might contribute to the pathogenesis; however, 
subsequent studies failed to validate this observation, so the hypothesis has not been further 
investigated.80,90 Thus, the mechanism of insulin resistance in pancreatic ductal 
adenocarcinoma needs further study.
β-cell dysfunction—An impaired β-cell response to oral glucose load, hyperglycaemic 
clamp, and glucagon stimulation has been shown in diabetes secondary to pancreatic 
cancer.37,88,91–93 In studies using the homoeostatic model assessment, β-cell function was 
markedly diminished in pancreatic ductal adenocarcinoma with impaired fasting glucose, 
whereas insulin resistance was only modestly increased.89 A β-cell toxic secretory product 
of pancreatic ductal adenocarcinoma has long been postulated based on the fact that 
supernatant from cell lines of pancreatic ductal adenocarcinoma inhibited insulin 
secretion.94 Microarray analysis of diabetogenic cell lines of pancreatic ductal 
adenocarcinoma led to identification of adrenomedullin as a candidate mediator of this 
effect.83,95 Adrenomedullin was shown to mediate pancreatic ductal adenocarcinoma-
induced inhibition of insulin secretion in β cells in various in-vitro and in-vivo tumour 
models of pancreatic ductal adenocarcinoma.83 Plasma concentrations of adrenomedullin 
were higher in participants with diabetes secondary to pancreatic cancer compared with 
those without diabetes and healthy controls.83 Adrenomedullin has previously been shown to 
be overexpressed in pancreatic ductal adenocarcinoma and enhances tumour 
aggressiveness.96–98 Thus, adrenomedullin, secreted by the cancerous pancreas in its hostile 
microenvironment, not only promoted invasive behaviour but also caused hyperglycaemia. 
Subsequently, adrenomedullin was identified in exosomes secreted by cancer cell lines, and 
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the effect of these supernatants on insulin secretion was shown to be mediated by 
adrenomedullin contained in exosomes.99,100
Influence of adipokines—Adipokines have been associated with the development of 
diabetes, obesity, and pancreatic ductal adenocarcinoma.101,102 Some of these adipokines 
have been proposed as potential biomarkers for early detection of pancreatic ductal 
adenocarcinoma, and are also believed to have a role in tumour development.102,103 One of 
these candidate markers, lipocalin 2 (LCN2; also known as neutrophil gelatinase associated 
lipocalin [NGAL]), has also been described in obesity associated with breast cancer.104–106 
LCN2 is elevated in the serum and visceral adipose tissue of obese individuals, and regulates 
adipose inflammation affecting glucose metabolism and insulin sensitivity.104,107 Other 
adipokines of interest in obesity-associated pancreatic ductal adenocarcinoma include leptin 
and adiponectin.108,109
Potential immunopathogenesis—Increased calprotectin (S100A8/A9) is detected in 
inflammation and various types of cancers.110 The N-terminus of the S100-A8 peptide has 
been proposed as a potential diabetogenic factor on the basis of proteomic findings in 
samples of pancreatic ductal adenocarcinoma, as well as observation of glucose utilisation of 
myoblasts exposed to the peptide.111 Another proteomic study found upregulation of S100-
A9 in pancreatic ductal adenocarcinoma tissues with diabetes compared with those without 
diabetes.112 S100A8/A9 is highly abundant in neutrophils and activated monocytes or 
macrophages, and these findings might reflect the myeloid cell infiltration observed even at 
early stages of pancreatic ductal adenocarcinoma development.113,114 A study using 
peripheral blood mononuclear cell gene profiling for pancreatic ductal adenocarcinoma 
proposed vanin-1 and matrix metalloproteinase-9 (MMP9) as biomarkers to discriminate 
diabetes secondary to pancreatic cancer from type 2 diabetes.34 A more recent study of 
blood and tissue mRNA also associated increased expression of MMP9, but not S100-A8, 
with diabetes secondary to pancreatic cancer.115 Macrophages upregulate MMP9 and S100-
A8 in response to TNFα and interleukin 1β— cytokines enriched in the tumour 
microenvironment.116–118 Additional insights suggest that this inflammatory environment 
might partly explain the β-cell dysfunction observed in pancreatic ductal adenocarcinoma, 
representing an important area of future research (appendix).
Clinical relevance
The new occurrence of diabetes in the context of pancreatic ductal adenocarcinoma has 
important clinical implications.119 New-onset diabetes might potentially be used for early 
detection of pancreatic ductal adenocarcinoma since it often comes before clinical diagnosis 
of pancreatic ductal adenocarcinoma by up to 24–36 months. In one study, 0.85% of 
participants with new-onset diabetes older than 50 years had pancreatic ductal 
adenocarcinoma.67 However, in view of this low prevalence of pancreatic ductal 
adenocarcinoma in the cohort of people with new-onset diabetes, additional features are 
needed to identify the high-risk population. Although typical demographic features and 
family history of diabetes do not discriminate between type 2 diabetes and diabetes 
secondary to pancreatic cancer, weight loss at the time of diabetes onset is more common in 
pancreatic ductal adenocarcinoma than in type 2 diabetes (59% vs 30%; p=0.02).120 A 
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recent study also showed a blunted serum pancreatic polypeptide response to mixed meal 
stimulation in those with new-onset diabetes secondary to pancreatic cancer compared with 
type 2 diabetes.121 However, the abnormal response was not observed in those with a tumour 
located on the body or tail of the pancreas, so this test might need to be coupled with other 
screening measures if the results are validated.
Additionally, diabetes is associated with negative clinical outcomes in those with pancreatic 
ductal adenocarcinoma. The presence of diabetes has also been identified as a predictor of 
worse survival in all stages of disease.122,123 Patients with diabetes also have increased risk 
of complications after surgery for pancreatic ductal adenocarcinoma, including pancreatic 
leaks, surgical site infections, intra-abdominal abscesses, and delayed gastric emptying.124 
However, to demonstrate causality between diabetes and these outcomes in pancreatic ductal 
adenocarcinoma is challenging because of the organ’s role in glucose homoeostasis, 
potential influence (positive or negative) of antidiabetic medications, variable glycaemic 
responses (including paradoxical improvement) after cancer-related treatments, and 
influence of diabetes duration (which was often not accounted for in previous studies).
Management of hyperglycaemia
There are no direct studies to inform decisions regarding the management of hyperglycaemia 
in diabetes secondary to pancreatic cancer. By contrast with chronic pancreatitis and other 
forms of diabetes, prevention of the long-term sequelae of diabetes is less relevant in this 
group of patients because of the shortened life expectancy. Rather, the primary treatment 
goal is to prevent short-term metabolic complications, which can lead to morbidity and delay 
cancer-related treatments. Metformin is an attractive drug in this patient group because of its 
reported antineoplastic properties, and studies suggesting its use might confer protection 
from development of pancreatic ductal adenocarcinoma. In patients with type 2 diabetes, 
case-control studies have suggested up to a 60% reduction in the risk of pancreatic ductal 
adenocarcinoma with metformin treatment, although data from recent meta-analyses have 
shown mixed results.125–127 In two phase 2 trials in metastatic pancreatic ductal 
adenocarcinoma, there was no difference in progression-free or overall survival in those who 
received metformin in addition to a standard chemotherapeutic regimen.128,129 Other data, 
albeit controversial, suggest that insulin and incretin-based therapies (GLP-1 analogues and 
oral DPP-4 inhibitors) might increase risk for developing pancreatic ductal 
adenocarcinoma.130 When hypoglycaemic agents are used, it is important to closely monitor 
glucose concentrations because the hyperglycaemia can improve, and often resolve, in those 
successfully treated with surgery or chemotherapy.71,82 Thus, metformin might be preferred 
as first-line therapy for mild hyperglycaemia, but there is a paucity of data to inform 
additional therapy.
Knowledge gaps
Our Review of type 3c diabetes reveals several important knowledge gaps. At a foundational 
level, a better understanding of the pathogenesis is needed to more accurately define and 
distinguish type 3c diabetes from other diabetes subtypes. Clinically, the associated 
pancreatic disorders are heterogeneous and preliminary data support the concept that the 
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mechanisms of hyperglycaemia differ in the various forms of type 3c diabetes. Further 
characterisation of the underlying mechanisms of disease, including genetic predis positions 
and physiological differences in β-cell function and insulin sensitivity, will help to 
discriminate the different forms of type 3c diabetes from the much more prevalent type 2 
diabetes. These insights are needed to develop validated diagnostic criteria and accurate 
disease prevalence estimates, and will permit further investigations into the potential use of 
new-onset diabetes for early detection of pancreatic ductal adenocarcinoma and therapeutic 
interventions for type 3c diabetes.
Future studies
The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer 
(CPDPC) was formed in 2015 to undertake a comprehensive clinical, epidemiological, and 
biological characterisation of patients to understand the complex relationships between 
chronic pancreatitis (including recurrent acute pancreatitis), diabetes, and pancreatic ductal 
adenocarcinoma. The key driving forces behind this effort include the increased risk for 
developing pancreatic ductal adenocarcinoma in those with chronic pancreatitis, particularly 
those with diabetes, and the increasing mortality rate of pancreatic ductal adenocarcinoma, 
which is expected to become the second leading cause of cancer death in the USA by 
2030.131 The CPDPC will enrol patients in longitudinal cohorts designed to identify 
biomarkers of these pancreatic diseases and more precisely define their relationships. These 
studies will address many of these gaps in knowledge, leading to earlier detection, 
prevention, and better treatment options for these patients.
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Acknowledgments
We thank David Whitcomb for his thoughtful review and comments regarding the manuscript. The content is solely 
the responsibility of the authors and does not necessarily represent the official views of the National Institutes of 
Health.
References
1. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2016; 
39(suppl 1):S13–22. [PubMed: 26696675] 
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert 
committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26(suppl 
1):S5–20. [PubMed: 12502614] 
3. Ewald N, Kaufmann C, Raspe A, Kloer HU, Bretzel RG, Hardt PD. Prevalence of diabetes mellitus 
secondary to pancreatic diseases (type 3c). Diabetes Metab Res Rev. 2012; 28:338–42. [PubMed: 
22121010] 
4. Xiao, AY., Tan, MLY., Wu, LM., et al. Global incidence and mortality of pancreatic diseases: a 
systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet 
Gastroenterol Hepatol. 2016. published online June 28. http://dx.doi.org/10.1016/
S2468-1253(16)30004-8
Hart et al. Page 13
Lancet Gastroenterol Hepatol. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
5. Yadav D, Timmons L, Benson JT, Dierkhising RA, Chari ST. Incidence, prevalence, and survival of 
chronic pancreatitis: a population-based study. Am J Gastroenterol. 2011; 106:2192–99. [PubMed: 
21946280] 
6. National Cancer Institute. SEER Cancer Statistics Factsheets: Pancreas Cancer. http://
seer.cancer.gov/statfacts/html/pancreas.html (accessed April 21, 2016).
7. Mohapatra S, Majumder S, Smyrk TC, et al. Diabetes mellitus is associated with an exocrine 
pancreatopathy: conclusions from a review of literature. Pancreas. 2016; 45:1104–10. [PubMed: 
26918874] 
8. Vujasinovic M, Zaletel J, Tepes B, et al. Low prevalence of exocrine pancreatic insufficiency in 
patients with diabetes mellitus. Pancreatology. 2013; 13:343–46. [PubMed: 23890131] 
9. Ewald N, Bretzel RG. Diabetes mellitus secondary to pancreatic diseases (type 3c)—are we 
neglecting an important disease? Eur J Intern Med. 2013; 24:203–06. [PubMed: 23375619] 
10. Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. 
Gastroenterology. 2000; 119:1324–32. [PubMed: 11054391] 
11. Rebours V, Boutron-Ruault MC, Schnee M, et al. The natural history of hereditary pancreatitis: a 
national series. Gut. 2009; 58:97–103. [PubMed: 18755888] 
12. Howes N, Lerch MM, Greenhalf W, et al. Clinical and genetic characteristics of hereditary 
pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004; 2:252–61. [PubMed: 15017610] 
13. Wang W, Guo Y, Liao Z, et al. Occurrence of and risk factors for diabetes mellitus in Chinese 
patients with chronic pancreatitis. Pancreas. 2011; 40:206–12. [PubMed: 21404458] 
14. Larsen S, Hilsted J, Tronier B, Worning H. Metabolic control and β cell function in patients with 
insulin-dependent diabetes mellitus secondary to chronic pancreatitis. Metabolism. 1987; 36:964–
67. [PubMed: 3309547] 
15. Whitcomb DC. Genetic risk factors for pancreatic disorders. Gastroenterology. 2013; 144:1292–
302. [PubMed: 23622139] 
16. Linde J, Nilsson LH, Barany FR. Diabetes and hypoglycemia in chronic pancreatitis. Scand J 
Gastroenterol. 1977; 12:369–73. [PubMed: 867001] 
17. Tiengo A, Segato T, Briani G, et al. The presence of retinopathy in patients with secondary 
diabetes following pancreatectomy or chronic pancreatitis. Diabetes Care. 1983; 6:570–74. 
[PubMed: 6653314] 
18. Briani G, Riva F, Midena E, et al. Prevalence of microangiopathic complications in hyperglycemia 
secondary to pancreatic disease. J Diabet Complications. 1988; 2:50–52. [PubMed: 2968358] 
19. Ziegler O, Candiloros H, Guerci B, Got I, Crea T, Drouin P. Lower-extremity arterial disease in 
diabetes mellitus due to chronic pancreatitis. Diabetes Metab. 1994; 20:540–45.
20. Cui Y, Andersen DK. Diabetes and pancreatic cancer. Endocr Relat Cancer. 2012; 19:F9–26. 
[PubMed: 22843556] 
21. Liao KF, Lai SW, Li CI, Chen WC. Diabetes mellitus correlates with increased risk of pancreatic 
cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol. 2012; 27:709–13. 
[PubMed: 21929650] 
22. Munigala S, Singh A, Gelrud A, Agarwal B. Predictors for pancreatic cancer diagnosis following 
new-onset diabetes mellitus. Clin Transl Gastroenterol. 2015; 6:e118. [PubMed: 26492440] 
23. Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis 
on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metab. 2012; 
14:1123–28. [PubMed: 22831166] 
24. Domschke S, Stock KP, Pichl J, Schneider MU, Domschke W. β-Cell reserve capacity in chronic 
pancreatitis. Hepatogastroenterology. 1985; 32:27–30. [PubMed: 3886512] 
25. Sherry NA, Tsai EB, Herold KC. Natural history of β-cell function in type 1 diabetes. Diabetes. 
2005; 54(suppl 2):S32–39. [PubMed: 16306337] 
26. Lundberg R, Beilman GJ, Dunn TB, et al. Early alterations in glycemic control and pancreatic 
endocrine function in nondiabetic patients with chronic pancreatitis. Pancreas. 2016; 45:565–71. 
[PubMed: 26918872] 
Hart et al. Page 14
Lancet Gastroenterol Hepatol. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
27. Nyboe Andersen B, Krarup T, Thorsgaard Pedersen NT, Faber OK, Hagen C, Worning H. β cell 
function in patients with chronic pancreatitis and its relation to exocrine pancreatic function. 
Diabetologia. 1982; 23:86–89. [PubMed: 6182047] 
28. Sasikala M, Talukdar R, Pavan kumar P, et al. β-cell dysfunction in chronic pancreatitis. Dig Dis 
Sci. 2012; 57:1764–72. [PubMed: 22383081] 
29. Schrader H, Menge BA, Schneider S, et al. Reduced pancreatic volume and β-cell area in patients 
with chronic pancreatitis. Gastroenterology. 2009; 136:513–22. [PubMed: 19041312] 
30. Andersson AK, Flodstrom M, Sandler S. Cytokine-induced inhibition of insulin release from 
mouse pancreatic β-cells deficient in inducible nitric oxide synthase. Biochem Biophys Res 
Commun. 2001; 281:396–403. [PubMed: 11181061] 
31. Boni-Schnetzler M, Boller S, Debray S, et al. Free fatty acids induce a proinflammatory response 
in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology. 2009; 150:5218–29. 
[PubMed: 19819943] 
32. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev 
Drug Discov. 2014; 13:465–76. [PubMed: 24854413] 
33. Pondugala PK, Sasikala M, Guduru VR, Rebala P, Nageshwar Reddy D. Interferon-γ decreases 
nuclear localization of Pdx-1 and triggers β-cell dysfunction in chronic pancreatitis. J Interferon 
Cytokine Res. 2015; 35:523–29. [PubMed: 25839229] 
34. Huang H, Dong X, Kang MX, et al. Novel blood biomarkers of pancreatic cancer-associated 
diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J 
Gastroenterol. 2010; 105:1661–69. [PubMed: 20571492] 
35. Seymour NE, Brunicardi FC, Chaiken RL, et al. Reversal of abnormal glucose production after 
pancreatic resection by pancreatic polypeptide administration in man. Surgery. 1988; 104:119–29. 
[PubMed: 3041640] 
36. Brunicardi FC, Chaiken RL, Ryan AS, et al. Pancreatic polypeptide administration improves 
abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab. 1996; 
81:3566–72. [PubMed: 8855802] 
37. Cersosimo E, Pisters PW, Pesola G, McDermott K, Bajorunas D, Brennan MF. Insulin secretion 
and action in patients with pancreatic cancer. Cancer. 1991; 67:486–93. [PubMed: 1985741] 
38. Kien CL, Horswill CA, Zipf WB, McCoy KS, O’Dorisio T. Elevated hepatic glucose production in 
children with cystic fibrosis. Pediatr Res. 1995; 37:600–05. [PubMed: 7603777] 
39. Seymour NE, Turk JB, Laster MK, et al. In vitro hepatic insulin resistance in chronic pancreatitis 
in the rat. J Surg Res. 1989; 46:450–56. [PubMed: 2654478] 
40. Seymour NE, Volpert AR, Lee EL, Andersen DK, Hernandez C. Alterations in hepatocyte insulin 
binding in chronic pancreatitis: effects of pancreatic polypeptide. Am J Surg. 1995; 169:105–09. 
[PubMed: 7817978] 
41. Goldstein JA, Kirwin JD, Seymour NE, Trachtenberg JE, Rademaker EA, Andersen DK. Reversal 
of in vitro hepatic insulin resistance in chronic pancreatitis by pancreatic polypeptide in the rat. 
Surgery. 1989; 106:1128–32. [PubMed: 2588116] 
42. Rabiee A, Galiatsatos P, Salas-Carrillo R, Thompson MJ, Andersen DK, Elahi D. Pancreatic 
polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of 
patients on insulin pump therapy. J Diabetes Sci Technol. 2011; 5:1521–28. [PubMed: 22226275] 
43. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic 
activation of IKK-β and NF-κB. Nat Med. 2005; 11:183–90. [PubMed: 15685173] 
44. Kiechl S, Wittmann J, Giaccari A, et al. Blockade of receptor activator of nuclear factor-κB 
(RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes 
mellitus. Nat Med. 2013; 19:358–63. [PubMed: 23396210] 
45. Zhou X, You S. Rosiglitazone inhibits hepatic insulin resistance induced by chronic pancreatitis 
and IKK-β/NF-κB expression in liver. Pancreas. 2014; 43:1291–98. [PubMed: 25036911] 
46. Niebisz-Cieślak AB, Karnafel W. Insulin sensitivity in chronic pancreatitis and features of insulin 
resistance syndrome. Pol Arch Med Wewn. 2010; 120:255–63. [PubMed: 20693955] 
47. Vlasakova Z, Bartos V, Spicak J. Diabetes mellitus in chronic pancreatitis and insulin sensitivity. 
Vnitr Lek. 2002; 48:878–81. [PubMed: 16737129] 
Hart et al. Page 15
Lancet Gastroenterol Hepatol. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
48. Yki-Jarvinen H, Kiviluoto T, Taskinen MR. Insulin resistance is a prominent feature of patients 
with pancreatogenic diabetes. Metabolism. 1986; 35:718–27. [PubMed: 3736412] 
49. Nosadini R, del Prato S, Tiengo A, et al. Insulin sensitivity, binding, and kinetics in pancreatogenic 
and type I diabetes. Diabetes. 1982; 31:346–55. [PubMed: 6759250] 
50. Muggeo M, Moghetti P, Faronato PP, et al. Insulin receptors on circulating blood cells from 
patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects. J 
Endocrinol Invest. 1987; 10:311–19. [PubMed: 3305682] 
51. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-
dependent) diabetes. Diabetologia. 1986; 29:46–52. [PubMed: 3514343] 
52. Knop FK, Vilsboll T, Hojberg PV, et al. The insulinotropic effect of GIP is impaired in patients 
with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic 
pancreatitis and normal glucose tolerance. Regul Pept. 2007; 144:123–30. [PubMed: 17692937] 
53. Vilsboll T, Knop FK, Krarup T, et al. The pathophysiology of diabetes involves a defective 
amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic 
polypeptide-regardless of etiology and phenotype. J Clin Endocrinol Metab. 2003; 88:4897–903. 
[PubMed: 14557471] 
54. Hedetoft C, Sheikh SP, Larsen S, Holst JJ. Effect of glucagon-like peptide 1(7–36)amide in insulin-
treated patients with diabetes mellitus secondary to chronic pancreatitis. Pancreas. 2000; 20:25–31. 
[PubMed: 10630380] 
55. Knop FK, Vilsboll T, Larsen S, et al. Increased postprandial responses of GLP-1 and GIP in 
patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J 
Physiol Endocrinol Metab. 2007; 292:E324–30. [PubMed: 16954337] 
56. Hornum M, Pedersen JF, Larsen S, Olsen O, Holst JJ, Knop FK. Increased postprandial response of 
glucagon-like peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insuffi ciency. 
Pancreatology. 2010; 10:201–17. [PubMed: 20460948] 
57. Ebert R, Creutzfeldt W. Reversal of impaired GIP and insulin secretion in patients with 
pancreatogenic steatorrhea following enzyme substitution. Diabetologia. 1980; 19:198–204. 
[PubMed: 6997121] 
58. Kuo P, Stevens JE, Russo A, et al. Gastric emptying, incretin hormone secretion, and postprandial 
glycemia in cystic fibrosis— effects of pancreatic enzyme supplementation. J Clin Endocrinol 
Metab. 2011; 96:E851–55. [PubMed: 21389144] 
59. Perano SJ, Couper JJ, Horowitz M, et al. Pancreatic enzyme supplementation improves the incretin 
hormone response and attenuates postprandial glycemia in adolescents with cystic fibrosis: a 
randomized crossover trial. J Clin Endocrinol Metab. 2014; 99:2486–93. [PubMed: 24670086] 
60. Rickels MR, Bellin M, Toledo FG, et al. Detection, evaluation and treatment of diabetes mellitus in 
chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology. 2013; 13:336–42. 
[PubMed: 23890130] 
61. Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. 
Pancreatology. 2011; 11:279–94. [PubMed: 21757968] 
62. Elashoff M, Matveyenko AV, Gier B, Elashoff ZR, Butler PC. Pancreatitis, pancreatic, and thyroid 
cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011; 141:150–56. 
[PubMed: 21334333] 
63. Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin 
resistance and β-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008; 9:193–205. 
[PubMed: 18200017] 
64. Dooley J, Tian L, Schonefeldt S, et al. Genetic predisposition for β cell fragility underlies type 1 
and type 2 diabetes. Nat Genet. 2016; 48:519–27. [PubMed: 26998692] 
65. Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-
associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011; 
20:779–92. [PubMed: 21357378] 
66. Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of 
cohort studies. Eur J Cancer. 2011; 47:1928–37. [PubMed: 21458985] 
Hart et al. Page 16
Lancet Gastroenterol Hepatol. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
67. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of 
pancreatic cancer following diabetes: a population-based study. gastroenterology. 2005; 129:504–
11. [PubMed: 16083707] 
68. Damiano J, Bordier L, Le Berre JP, et al. Should pancreas imaging be recommanded in patients 
over 50 years when diabetes is discovered because of acute symptoms? Diabetes Metab. 2004; 
30:203–07. [PubMed: 15223996] 
69. Illes D, Terzin V, Holzinger G, et al. New-onset type 2 diabetes mellitus—a high-risk group 
suitable for the screening of pancreatic cancer? Pancreatology. 2016; 16:266–71. [PubMed: 
26777407] 
70. Ogawa Y, Tanaka M, Inoue K, et al. A prospective pancreatographic study of the prevalence of 
pancreatic carcinoma in patients with diabetes mellitus. Cancer. 2002; 94:2344–49. [PubMed: 
12015758] 
71. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical 
profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008; 134:981–87. 
[PubMed: 18395079] 
72. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared 
to common cancers. Pancreas. 2013; 42:198–201. [PubMed: 23000893] 
73. Aggarwal G, Rabe KG, Petersen GM, Chari ST. New-onset diabetes in pancreatic cancer: a study 
in the primary care setting. Pancreatology. 2012; 12:156–61. [PubMed: 22487526] 
74. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic 
cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting 
glucose values prior to diagnosis. Am J Gastroenterol. 2007; 102:2157–63. [PubMed: 17897335] 
75. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II 
diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005; 92:2076–83. 
[PubMed: 15886696] 
76. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced 
paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013; 10:423–33. [PubMed: 23528347] 
77. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is 
associated with impaired glucose metabolism. Eur J Surg Suppl. 1993; 159:101–07.
78. Permert J, Adrian TE, Jacobsson P, Jorfelt L, Fruin AB, Larsson J. Is profound peripheral insulin 
resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg. 
1993; 165:61–66. [PubMed: 8380314] 
79. Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence 
and temporal association with diagnosis of cancer. Gastroenterology. 2008; 134:95–101. [PubMed: 
18061176] 
80. Chari ST, Klee GG, Miller LJ, Raimondo M, DiMagno EP. Islet amyloid polypeptide is not a 
satisfactory marker for detecting pancreatic cancer. Gastroenterology. 2001; 121:640–45. 
[PubMed: 11522748] 
81. Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study Group. Diabetes and the 
risk of pancreatic cancer. N Engl J Med. 1994; 331:81–84. [PubMed: 8208269] 
82. Gardner TB, Hessami N, Smith KD, et al. The effect of neoadjuvant chemoradiation on pancreatic 
cancer-associated diabetes mellitus. Pancreas. 2014; 43:1018–21. [PubMed: 25000339] 
83. Aggarwal G, Ramachandran V, Javeed N, et al. Adrenomedullin is upregulated in patients with 
pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology. 2012; 
143:1510–17. [PubMed: 22960655] 
84. Basso D, Valerio A, Seraglia R, et al. Putative pancreatic cancer-associated diabetogenic factor: 
2030 MW peptide. Pancreas. 2002; 24:8–14. [PubMed: 11741177] 
85. Valerio A, Basso D, Brigato L, et al. Glucose metabolic alterations in isolated and perfused rat 
hepatocytes induced by pancreatic cancer conditioned medium: a low molecular weight factor 
possibly involved. Biochem Biophys Res Commun. 1999; 257:622–28. [PubMed: 10198261] 
86. Basso D, Millino C, Greco E, et al. Altered glucose metabolism and proteolysis in pancreatic 
cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray 
analysis of 5000 skeletal muscle genes. Gut. 2004; 53:1159–66. [PubMed: 15247186] 
Hart et al. Page 17
Lancet Gastroenterol Hepatol. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
87. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism 
after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993; 80:1047–50. [PubMed: 
8402064] 
88. Permert J, Larsson J, Fruin AB, et al. Islet hormone secretion in pancreatic cancer patients with 
diabetes. Pancreas. 1997; 15:60–68. [PubMed: 9211494] 
89. Chari ST, Zapiach M, Yadav D, Rizza RA. β-cell function and insulin resistance evaluated by 
HOMA in pancreatic cancer subjects with varying degrees of glucose intolerance. Pancreatology. 
2005; 5:229–33. [PubMed: 15855820] 
90. Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic 
cancer and diabetes. N Engl J Med. 1994; 330:313–18. [PubMed: 8277951] 
91. Schwarts SS, Zeidler A, Moossa AR, Kuku SF, Rubenstein AH. A prospective study of glucose 
tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am J 
Dig Dis. 1978; 23:1107–14. [PubMed: 367155] 
92. Basso D, Plebani M, Fogar P, et al. β-cell function in pancreatic adenocarcinoma. Pancreas. 1994; 
9:332–35. [PubMed: 8022755] 
93. Fox JN, Frier BM, Armitage M, Ashby JP. Abnormal insulin secretion in carcinoma of the 
pancreas: response to glucagon stimulation. Diabet Med. 1985; 2:113–16. [PubMed: 2952394] 
94. Wang F, Larsson J, Abdiu A, et al. Dissociated secretion of islet amyloid polypeptide and insulin in 
serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines. Int J 
Pancreatol. 1997; 21:157–64. [PubMed: 9209957] 
95. Sekine N, Takano K, Kimata-Hayashi N, Kadowaki T, Fujita T. Adrenomedullin inhibits insulin 
exocytosis via pertussis toxin-sensitive G protein-coupled mechanism. Am J Physiol Endocrinol 
Metab. 2006; 291:E9–14. [PubMed: 16760337] 
96. Ramachandran V, Arumugam T, Langley R, et al. The ADMR receptor mediates the effects of 
adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One. 
2009; 4:e7502. [PubMed: 19847298] 
97. Ramachandran V, Arumugam T, Hwang RF, Greenson JK, Simeone DM, Logsdon CD. 
Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in 
an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res. 2007; 67:2666–75. 
[PubMed: 17363587] 
98. Keleg S, Kayed H, Jiang X, et al. Adrenomedullin is induced by hypoxia and enhances pancreatic 
cancer cell invasion. Int J Cancer. 2007; 121:21–32. [PubMed: 17290391] 
99. Javeed N, Sagar G, Dutta SK, et al. Pancreatic cancer-derived exosomes cause paraneoplastic β-
cell dysfunction. Clin Cancer Res. 2015; 21:1722–33. [PubMed: 25355928] 
100. Korc M. Pancreatic cancer-associated diabetes is an “exosomopathy”. Clin Cancer Res. 2015; 
21:1508–10. [PubMed: 25645860] 
101. El-Mesallamy HO, Hamdy NM, Sallam AA. Effect of obesity and glycemic control on serum 
lipocalins and insulin-like growth factor axis in type 2 diabetic patients. Acta Diabetol. 2013; 
50:679–85. [PubMed: 22307870] 
102. Leung L, Radulovich N, Zhu CQ, et al. Lipocalin2 promotes invasion, tumorigenicity and 
gemcitabine resistance in pancreatic ductal adenocarcinoma. PLoS One. 2012; 7:e46677. 
[PubMed: 23056397] 
103. Kausr S, Chakraborty S, Baine MJ, et al. Potentials of plasma NGAL and MIC-1 as biomarker(s) 
in the diagnosis of lethal pancreatic cancer. PLoS One. 2013; 8:e55171. [PubMed: 23383312] 
104. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase 
associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta. 2012; 
1826:129–69. [PubMed: 22513004] 
105. Chung JO, Park SY, Cho DH, Chung DJ, Chung MY. Plasma neutrophil gelatinase-associated 
lipocalin levels are positively associated with diabetic retinopathy in patients with type 2 
diabetes. Diabet Med. 2016; published online April 26. doi: 10.1111/dme.13141
106. Drew BG, Hamidi H, Zhou Z, et al. Estrogen receptor (ER) α-regulated lipocalin 2 expression in 
adipose tissue links obesity with breast cancer progression. J Biol Chem. 2015; 290:5566–81. 
[PubMed: 25468909] 
Hart et al. Page 18
Lancet Gastroenterol Hepatol. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
107. Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Increased adipose tissue expression of 
lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and 
metalloproteinase-9 activities in humans. J Mol Med (Berl). 2009; 87:803–13. [PubMed: 
19466389] 
108. Stolzenberg-Solomon RZ, Newton CC, Silverman DT, et al. Circulating leptin and risk of 
pancreatic cancer: a pooled analysis from 3 cohorts. Am J Epidemiol. 2015; 182:187–97. 
[PubMed: 26085045] 
109. Gasiorowska A, Talar-Wojnarowska R, Kaczka A, Borkowska A, Czupryniak L, Malecka-Panas 
E. Role of adipocytokines and its correlation with endocrine pancreatic function in patients with 
pancreatic cancer. Pancreatology. 2013; 13:409–14. [PubMed: 23890140] 
110. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. 
Biochem Pharmacol. 2006; 72:1622–31. [PubMed: 16846592] 
111. Basso D, Greco E, Fogar P, et al. Pancreatic cancer-derived S-100A8 N-terminal peptide: a 
diabetes cause? Clin Chim Acta. 2006; 372:120–28. [PubMed: 16678810] 
112. Wang WS, Liu XH, Liu LX, Jin DY, Yang PY, Wang XL. Identification of proteins implicated in 
the development of pancreatic cancer-associated diabetes mellitus by iTRAQ-based quantitative 
proteomics. J Proteomics. 2013; 84:52–60. [PubMed: 23571023] 
113. Liou GY, Doppler H, Necela B, et al. Macrophage-secreted cytokines drive pancreatic acinar-to-
ductal metaplasia through NF-κB and MMPs. J Cell Biol. 2013; 202:563–77. [PubMed: 
23918941] 
114. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the 
immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007; 67:9518–27. 
[PubMed: 17909062] 
115. Moz S, Basso D, Padoan A, et al. Blood expression of matrix metalloproteinases 8 and 9 and of 
their inducers S100A8 and S100A9 supports diagnosis and prognosis of PDAC-associated 
diabetes mellitus. Clin Chim Acta. 2016; 456:24–30. [PubMed: 26923392] 
116. Saren P, Welgus HG, Kovanen PT. TNF-α and IL-1β selectively induce expression of 92-kDa 
gelatinase by human macrophages. J Immunol. 1996; 157:4159–65. [PubMed: 8892653] 
117. Xu K, Geczy CL. IFN-γ and TNF regulate macrophage expression of the chemotactic S100 
protein S100A8. J Immunol. 2000; 164:4916–23. [PubMed: 10779802] 
118. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging 
role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl 
Med. 2006; 4:48. [PubMed: 17096856] 
119. Hart PA, Chari ST. Diabetes mellitus and pancreatic cancer: why the association matters? 
Pancreas. 2013; 42:1207–09. [PubMed: 24152945] 
120. Hart PA, Kamada P, Rabe KG, et al. Weight loss precedes cancer-specific symptoms in pancreatic 
cancer-associated diabetes mellitus. Pancreas. 2011; 40:768–72. [PubMed: 21654538] 
121. Hart PA, Baichoo E, Bi Y, Hinton A, Kudva YC, Chari ST. Pancreatic polypeptide response to a 
mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus. Pancreatology. 
2015; 15:162–66. [PubMed: 25766398] 
122. Walter U, Kohlert T, Rahbari NN, Weitz J, Welsch T. Impact of preoperative diabetes on long-
term survival after curative resection of pancreatic adenocarcinoma: a systematic review and 
meta-analysis. Ann Surg Oncol. 2014; 21:1082–89. [PubMed: 24322532] 
123. Yuan C, Rubinson DA, Qian ZR, et al. Survival among patients with pancreatic cancer and long-
standing or recent-onset diabetes mellitus. J Clin Oncol. 2015; 33:29–35. [PubMed: 25403204] 
124. Raghavan SR, Ballehaninna UK, Chamberlain RS. The impact of perioperative blood glucose 
levels on pancreatic cancer prognosis and surgical outcomes: an evidence-based review. Pancreas. 
2013; 42:1210–17. [PubMed: 24152946] 
125. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of 
pancreatic cancer. Gastroenterology. 2009; 137:482–88. [PubMed: 19375425] 
126. Wang Z, Lai ST, Xie L, et al. Metformin is associated with reduced risk of pancreatic cancer in 
patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin 
Pract. 2014; 106:19–26. [PubMed: 24837144] 
Hart et al. Page 19
Lancet Gastroenterol Hepatol. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
127. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabetic medications 
and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-
analysis. Am J Gastroenterol. 2013; 108:510–19. [PubMed: 23399556] 
128. Reni M, Dugnani E, Cereda S, et al. (Ir)relevance of metformin treatment in patients with 
metastatic pancreatic cancer: an open-label, randomized phase II trial. Clin Cancer Res. 2016; 
22:1076–85. [PubMed: 26459175] 
129. Kordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic 
cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015; 
16:839–47. [PubMed: 26067687] 
130. Andersen DK, Andren-Sandberg A, Duell EJ, et al. Pancreatitis-diabetes-pancreatic cancer: 
summary of an NIDDK-NCI workshop. Pancreas. 2013; 42:1227–37. [PubMed: 24152948] 
131. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting 
cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas 
cancers in the United States. Cancer Res. 2014; 74:2913–21. [PubMed: 24840647] 
Hart et al. Page 20
Lancet Gastroenterol Hepatol. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Panel: Subclassifications of causes of type 3c diabetes grouped according 
to their potential mechanisms
Congenital or acquired complete absence of islets
• Pancreatic agenesis
• Pancreatectomy (total)
Acquired partial absence of functional islets
• Chronic pancreatitis*
• Pancreatectomy (partial)
• Severe acute pancreatitis
• Cystic fibrosis
• Haemochromatosis
Paraneoplastic
• Pancreatic ductal adenocarcinoma
Other
• Transient† hyperglycaemia of acute pancreatitis
*Includes tropical pancreatitis, which was previously referred to as fibrocalculous 
pancreatopathy. †Hyperglycaemia secondary to acute pancreatitis can persist for weeks.
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Search strategy and selection criteria
We identified references for this Review through a search of PubMed for articles 
published between Jan 1, 1980, and March 1, 2016, with the following search terms: 
“type 3c OR pancreatogenic OR pancreatogenous OR pancreatic cancer OR pancreatic 
neoplasms OR pancreatitis” AND “diabetes OR diabetes mellitus”. We identified 
additional articles through chaining, by examining the bibliographies of these selected 
articles, and our own files. We included only papers published in English, and selected 
the final references on the basis of originality and relevance to the defined scope of this 
Review.
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Figure. Prevalence and causes of type 3c diabetes mellitus
(A) Prevalence of type 3c diabetes in a cohort of 1868 participants with diabetes. (B) 
Frequency of different causes in the 117 participants with type 3c diabetes. Reproduced 
from Ewald and colleagues,3 by permission of John Wiley and Sons.
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Table
Studies assessing the effect of PERT on incretin production and glycaemia in participants with EPI
Ebert and Creutzfeldt 
198057
Knop and colleagues 
200755
Kuo and colleagues 
201158
Perano and colleagues 
201459
Disease state Chronic pancreatitis with 
EPI
Chronic pancreatitis with 
EPI
Cystic fibrosis with 
EPI
Cystic fibrosis with EPI
Glycaemic status of cases 
(n)
IGT (16) DM (4), IGT (3), normal 
(1)
IGT (1), normal (4) DM (2), normal (12)
Glycaemic status of controls 
(n)
Normal (14) Normal (8) Normal (6) Normal (7)
Weight or BMI (cases vs 
controls)
59.7 vs 62 kg 21 vs 23 kg/m2 20 vs 21.3 kg/m2 BMI Z scores: 0.12 vs 
0.2
Mean age (cases vs controls; 
years)
40 vs 17 57 vs 58 253.8 vs 21.7 13.1 vs 14.6
Meal Liquid mixed meal Liquid mixed meal Mashed potatoes with 
olive oil
High fat pancake
Meal composition (% 
calories of fat/carbohydrates/
protein)
26%/60%/14% 27.7%/58%/9.5% 6l%/39%/0% 75%/25%/0%
Dose of lipase administered 
in PERT
N/A* 50000 U 100000 U 50 000 IU
Effect of PERT on 
postprandial AUC
 Total GLP-1 N/A ↑ ↔/↑ ↑
 Total GIP ↑ ↑ ↑ ↑
 Insulin ↑ ↑ ↔ ↔
 Glucose ↓ ↔ ↓ ↓
 Glucagon N/A ↑ ↔/↑ ↑
EPI=exocrine pancreatic insufficiency. IGT=impaired glucose tolerance. DM=diabetes mellitus. BMI=body-mass index. PERT=pancreatic enzyme 
replacement therapy. AUC=area under the curve. GLP-1=glucagon-like peptide-1. N/A=not available. GIP=glucose-dependent insulinotropic 
polypepti. ↑ ncreased. ↔ no change. ↓ecreased.
*
Participants were given 9 g of pancreatin before the study; however, the exact dose of lipase administered was not available.
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